JP2005522432A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522432A5
JP2005522432A5 JP2003565480A JP2003565480A JP2005522432A5 JP 2005522432 A5 JP2005522432 A5 JP 2005522432A5 JP 2003565480 A JP2003565480 A JP 2003565480A JP 2003565480 A JP2003565480 A JP 2003565480A JP 2005522432 A5 JP2005522432 A5 JP 2005522432A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003565480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522432A (ja
Filing date
Publication date
Priority claimed from GB0202680A external-priority patent/GB0202680D0/en
Priority claimed from GB0222616A external-priority patent/GB0222616D0/en
Application filed filed Critical
Priority claimed from PCT/GB2003/000462 external-priority patent/WO2003066056A1/en
Publication of JP2005522432A publication Critical patent/JP2005522432A/ja
Publication of JP2005522432A5 publication Critical patent/JP2005522432A5/ja
Withdrawn legal-status Critical Current

Links

JP2003565480A 2002-02-05 2003-02-04 ニューロン成長の促進方法 Withdrawn JP2005522432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202680A GB0202680D0 (en) 2002-02-05 2002-02-05 Novel method
GB0222616A GB0222616D0 (en) 2002-09-30 2002-09-30 Novel method
PCT/GB2003/000462 WO2003066056A1 (en) 2002-02-05 2003-02-04 Method of promoting neuronal growth

Publications (2)

Publication Number Publication Date
JP2005522432A JP2005522432A (ja) 2005-07-28
JP2005522432A5 true JP2005522432A5 (cg-RX-API-DMAC7.html) 2006-03-16

Family

ID=27736189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565480A Withdrawn JP2005522432A (ja) 2002-02-05 2003-02-04 ニューロン成長の促進方法

Country Status (5)

Country Link
US (1) US20070270432A1 (cg-RX-API-DMAC7.html)
EP (1) EP1471912A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005522432A (cg-RX-API-DMAC7.html)
AU (1) AU2003244452A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066056A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
JP4571507B2 (ja) 2002-12-18 2010-10-27 スベン ライフ サイエンシズ リミティド セロトニン受容体親和性を有する四環系3−置換インドール
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ATE430752T1 (de) 2004-01-02 2009-05-15 Suven Life Sciences Ltd Neue indenoä2,1-aüindene und isoindolä2,1-aüindol
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
AU2008246947B2 (en) 2007-05-03 2011-03-31 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
CA2703157C (en) 2007-10-26 2013-02-05 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
KR101608499B1 (ko) 2013-10-08 2016-04-01 이화여자대학교 산학협력단 4-니트로인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Similar Documents

Publication Publication Date Title
HRP20161657T1 (hr) Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
MY148487A (en) Biphenyl derivatives
CA2364718A1 (en) Monoamine reuptake inhibitors for treatment of cns disorders
JP2006526031A5 (cg-RX-API-DMAC7.html)
MY130803A (en) New quinuclidine amide derivatives
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
JP2007521280A5 (cg-RX-API-DMAC7.html)
NO20050883D0 (no) Ny fremgangsmate for syntesen (IS)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
ATE442135T1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
EP2397476A3 (en) Indole derivative having PGD2 receptor antagonist activity
JP2005504782A5 (cg-RX-API-DMAC7.html)
FR2882556B1 (fr) Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
DE60302157D1 (de) Opioidrezeptorantagonisten
JP2008513510A5 (cg-RX-API-DMAC7.html)
WO2006066173A3 (en) Novel mch receptor antagonists
JP2004532828A5 (cg-RX-API-DMAC7.html)
BR0316895A (pt) Composto, processo para a preparação do composto, composição farmacêutica, novos intermediários, processo para a preparação dos novos intermediários e uso do composto
WO2007039462A3 (en) Indane derivatives as mch receptor antagonists
RU2000100362A (ru) Применение специфического антагониста 5нт2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне
NO20050888D0 (no) Ny fremgangsmate for syntesen av 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20063602L (no) Benzyl(iden)-laktam-derivater